JAK Inhibitors in Inflammatory Skin Diseases: A 15,427-Patient Systematic Review and Meta-analysis of Clinical Trial and Real-World Outcomes.

What was studied

This review looked at JAK inhibitors for skin diseases with inflammation. It covered psoriasis, vitiligo, hidradenitis suppurativa, alopecia areata and atopic dermatitis. It asked how well and how safely they work, also over the long run. The team searched major databases up to May 2025. They took in trials and real-world studies.

What they found

The review pooled 68 studies with 15,427 patients. The studies were 12 real-world cohorts, 14 open-label extensions and 42 RCTs. JAK inhibitors taken by mouth did better than placebo across many conditions. Those put on the skin worked for atopic dermatitis and vitiligo. They helped little in alopecia areata. Safety looked alike across drugs. Upper airway infections were more common than with placebo. So was herpes zoster coming back. Rare but serious events did occur. These included cancers, blood clots in veins and major heart events.

What it means for patients

The authors say JAK inhibitors work well across several skin diseases with inflammation. They say safety needs ongoing checks, mostly in people with heart risk factors. They say selective JAK1 inhibitors appear to give the most favorable balance for atopic dermatitis. This view rests on comparisons between studies.

Why it is not certain yet

JAK1/2 inhibitors looked stronger for alopecia areata. The gap did not reach statistical significance. The authors say long-term safety and comparisons are hard to judge. Controlled trials were short. Diverse groups were under-represented. Comparisons were indirect.

Source

JAK Inhibitors in Inflammatory Skin Diseases: A 15,427-Patient Systematic Review and Meta-analysis of Clinical Trial and Real-World Outcomes.

We restate facts from the source record in our own words. The original wording belongs to its publisher.